Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI Biopharma Biotech
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials

Biopharma

The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
What healthcare payers reward: adherence versus outcomes What healthcare payers reward: adherence versus outcomes
Blog February 2, 2026
What healthcare payers reward: adherence versus outcomes
Realizing the value of convenience: payer engagement strategies for pharmas Realizing the value of convenience: payer engagement strategies for pharmas
Blog January 21, 2026
Realizing the value of convenience: payer engagement strategies for pharmas
Understanding the epidemiology of SMA Understanding the epidemiology of SMA
Blog December 18, 2025
Understanding the epidemiology of SMA
Forecasting target markets using epidemiology data: how Clarivate does it Forecasting target markets using epidemiology data: how Clarivate does it
Blog December 8, 2025
Forecasting target markets using epidemiology data: how Clarivate does it
Machine curation in action: a new approach to essential tremor epidemiology Machine curation in action: a new approach to essential tremor epidemiology
Blog November 17, 2025
Machine curation in action: a new approach to essential tremor epidemiology
Seven companies forging new paths in women’s health Seven companies forging new paths in women’s health
Blog November 13, 2025
Seven companies forging new paths in women’s health
Six companies enabling precision interventions for “undruggable” targets Six companies enabling precision interventions for “undruggable” targets
Blog October 7, 2025
Six companies enabling precision interventions for “undruggable” targets
GLP-1 weight loss access comes down to a dogfight in the U.S. GLP-1 weight loss access comes down to a dogfight in the U.S.
Blog October 3, 2025
GLP-1 weight loss access comes down to a dogfight in the U.S.